Erratum: Long-term effects of s-KL treatment in wild-type mice: Enhancing longevity, physical well-being, and neurological resilience (Molecular Therapy (2025) 33(4) (1449–1465), (S1525001625001200), (10.1016/j.ymthe.2025.02.030))

(Molecular Therapy 33, April 2025; 1449–1465) In the originally published version of this article, an unintentional mistake occurred in the legend of Figure 1. Specifically, a portion of the legend corresponding to Figure 1A was mistakenly duplicated in the legend for Figure 1E. The correct version of the complete legend for Figure 1 is provided below. The authors sincerely apologize for this oversight and for any inconvenience it may have caused to the readers. Figure 1. Longevity experiment follow-up and AAV treatment effectivity assessment. (A) Schematic representation of the experimental plan. AAV9, adeno-associated virus serotype 9; IV, intravenous injection; ICV, intracerebroventricular injection. (B) Body weight follow-up. (C) Violin plots of the median survival of the different treatments tested in males. (D) Longevity of the different male groups represented with Kaplan-Meyer longevity curves. Mean ± SEM, n =11–12. (E) s-KL gene expression analysis in the liver. Data presented as fold change expression compared to null-treated animals. (F) Quantification of total s-KL protein concentration in serum. Data presented as mean ± SEM, n = 4; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.001.